New targeted pill may keep ALK lung cancer in check after standard treatment
NCT ID NCT07235306
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the targeted drug ensartinib can help people with ALK-mutated stage III lung cancer that cannot be removed by surgery. After completing standard chemoradiotherapy, 45 participants will receive either ensartinib or a placebo to see if the drug delays cancer growth. The goal is to improve disease control without a cure, as ongoing treatment is needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
- Brain tumor patients with severe symptoms may get a new treatment option
- New drug combo aims to fight lung cancer after chemoradiation
- New immunotherapy combo aims to improve lung cancer outcomes
- Can what you eat during cancer treatment change your survival?
- Rectal cancer breakthrough: could a new drug combo save your rectum?